Near-term strategies for biotech drug developers facing shifting healthcare dynamics
A dynamic convergence of economic, legislative, scientific, and technological influences is molding the future of the healthcare industry – with implications for biotech companies. Healthcare environments are becoming increasingly complex as drug developers increasingly make the transition to next-generation therapeutics, driving demand for clinical innovation. Against this backdrop, the industry continues to pioneer new approaches to engaging with patients, clinical trial teams, and healthcare providers. During a recent panel discussion, Goldman Sachs and Parexel shared perspectives on emerging trends and high-level developments to help biotechs plan their short- and near-term strategies.
Get more insights from our recent panel discussion with Goldman Sachs, entitled “Decoding Healthcare’s Future: A comprehensive analysis of investment, clinical research and regulatory dynamics.”
The views and opinions expressed by the authors are their own and are for informational purposes only. They do not constitute a recommendation by Goldman Sachs, or Parexel, for you to take any action.
Related Insights
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Webinar
Regulatory roadmap for biotechs: Effective strategies for streamlined early phase development
May 6, 2025
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Playbook
Early-phase development strategies for navigating regulatory complexity in the EU
Apr 29, 2024
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Blog
Overcoming risks in Phase 3 trials to accelerate time to market
Jan 22, 2025
Blog
Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development
Jan 22, 2025
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Related Insights
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Webinar
Regulatory roadmap for biotechs: Effective strategies for streamlined early phase development
May 6, 2025
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Playbook
Early-phase development strategies for navigating regulatory complexity in the EU
Apr 29, 2024
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Blog
Overcoming risks in Phase 3 trials to accelerate time to market
Jan 22, 2025
Blog
Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development
Jan 22, 2025
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023